Clinical Trials
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Studies listed here represent active and ongoing clinical trials in the United States and Canada. Please click on the links for more information on each study including eligibility requirements and study locations. Studies listed are intended to provide a reference for trials related to rheumatologic skin disease, but the list is not comprehensive nor are the studies included specifically endorsed by RDS.
Lupus
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital Mon, Nov 15, 2021
- The Expression Profile of New Complement Components in Childhood Lupus Nephritis Mon, Oct 18, 2021
- A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care Wed, Jul 14, 2021
- A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care Thu, May 20, 2021
- Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus Mon, Aug 31, 2020
- Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation Wed, Mar 25, 2020
Dermatomyositis
- Longitudinal Study for Central Nervous System Vasculitis Tue, Feb 21, 2023
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma Fri, Nov 18, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Thu, Sep 01, 2022
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis Thu, Aug 04, 2022
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Wed, Jun 29, 2022
- Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) Mon, Jun 13, 2022
- Longitudinal Study for Central Nervous System Vasculitis Tue, Feb 21, 2023
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma Fri, Nov 18, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Thu, Sep 01, 2022
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis Thu, Aug 04, 2022
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Wed, Jun 29, 2022
- Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) Mon, Jun 13, 2022
- Longitudinal Study for Central Nervous System Vasculitis Tue, Feb 21, 2023
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma Fri, Nov 18, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Thu, Sep 01, 2022
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis Thu, Aug 04, 2022
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Wed, Jun 29, 2022
- Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) Mon, Jun 13, 2022
Systemic sclerosis
- Longitudinal Study for Central Nervous System Vasculitis Tue, Feb 21, 2023
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma Fri, Nov 18, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Thu, Sep 01, 2022
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis Thu, Aug 04, 2022
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Wed, Jun 29, 2022
- Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) Mon, Jun 13, 2022
Morphea
- Longitudinal Study for Central Nervous System Vasculitis Tue, Feb 21, 2023
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma Fri, Nov 18, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Thu, Sep 01, 2022
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis Thu, Aug 04, 2022
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Wed, Jun 29, 2022
- Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) Mon, Jun 13, 2022
Vasculitis
- Longitudinal Study for Central Nervous System Vasculitis Tue, Feb 21, 2023
- Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus Mon, Feb 13, 2023
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus Mon, Feb 06, 2023
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Tue, Nov 22, 2022
- Phenotyping of Chronic Pain in Diffused Systemic Scleroderma Fri, Nov 18, 2022
- Screening Biomarkers for Severe Lupus Based on Multi-omics Studies Wed, Sep 14, 2022
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Thu, Sep 01, 2022
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis Thu, Aug 04, 2022
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Wed, Jun 29, 2022
- Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) Mon, Jun 13, 2022
Clinical Registries
Lupus:
Cutaneous Lupus Registry at University of Pennsylvania Medical Center in Philadelphia, PA
Dermatologists at Penn established a registry for cutaneous lupus patients in 2006 to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. The database includes a blood and tissue bank CLE Tissue Bank, which was started at Penn in 2009 as a foundation for genetic, biomarker and pathophysiologic studies.
The principal investigator for the study is Victoria Werth, MD, Professor of Dermatology at the University of Pennsylvania, an expert in the treatment of cutaneous lupus. For more information, please go to
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html
Cutaneous Lupus Registry at University of Texas Southwestern Medical Center in Dallas, TX
Dermatologists at UT Southwestern have established a registry for cutaneous lupus patients and their relatives in order to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. This registry will provide a resource for investigators to make discoveries in regards to both the clinical and molecular aspects of the disease. The principal investigator for the study is Benjamin Chong, MD, assistant professor of dermatology at UT Southwestern, director of the connective tissue diseases clinic, and an expert in the treatment of cutaneous lupus. Participants will receive newsletters detailing the progress of the registry annually. Registration of study participants, which will require an in-person evaluation and consent, is already underway. For more information, please go to
Dermatomyositis:
Dermatomyositis Patient Registry at Stanford University Medical Center in Palo Alto, CA
We are interested in enrolling patients with dermatomyositis in order to better understand the disease and help find more effective and personalized therapies. Participants are asked to donate a blood sample as well as skin biopsy. If interested, please contact one of the two participating sites:
Stanford Department of Dermatology
Principal Investigator: David Fiorentino, MD, PhD
Contact: Amanda Foster
650-421-6103
Amfoster@stanford.edu
Dermatomyositis Patient Registry at University of Pennsylvania Medical Center in Philadelphia, PA
This is a study of dermatomyositis subjects who are followed during regularly scheduled clinic visits and are asked to provide data leading to evaluation of clinical responsiveness of their skin disease. Participants can donate a blood sample as well as skin biopsy. Studies relate to effectiveness of current treatments, studies to better understand the causes of the disease, and ways to improve treatments. If interested, please contact one of the two participating sites:
University of Pennsylvania
Principal Investigator: Victoria Werth, M.D.
Contact: Joyce Okawa
Phone: 215-898-0168
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html